Linked Life Data

2457420

Source:http://linkedlifedata.com/resource/pubmed/id/2457420

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
1988-10-3
pubmed:abstractText
Twenty patients with malignant hepatoma were treated with sequential intraarterial doxorubicin (72-hour continuous infusion) followed by systemic 5-fluorouracil (5-FU) and semustine (methyl CCNU). Objective tumor responses were seen in three patients (15%). The durations of response were 6, 19, and 27+ months, respectively. Median patient survival was 7 months. A variety of problems were encountered with the use of transcutaneous angiographic catheters for doxorubicin administration, including inability to adequately perfuse the liver, sepsis, and catheter dislodgement during chemotherapy infusion. Although some patients experienced palliation of reasonable duration, we do not believe that the overall results warrant further studies of this regimen.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0008-543X
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
62
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1041-3
pubmed:dateRevised
2007-11-14
pubmed:meshHeading
pubmed:year
1988
pubmed:articleTitle
Chemotherapy of malignant hepatomas with sequential intraarterial doxorubicin and systemic 5-fluorouracil and semustine.
pubmed:affiliation
Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S.